Pacira BioSciences (FRA:82P) Inventories, Finished Goods: €61.1 Mil (As of Mar. 2026)


FRA:82P Pacira BioSciences Inc FRA:82P
79 GF Score
Price €22.00
GF Value €25.64
! 8 Warning Signs
View Full Analysis

What is Pacira BioSciences Inventories, Finished Goods?

Pacira BioSciences FRA:82P 79 Inventories, Finished Goods is €61.1 Mil as of Mar. 2026. GuruFocus rates FRA:82P with a GF Score™ of 79/100 and a GF Value™ of €25.64. The stock has 8 warning signs investors should review.

Pacira BioSciences's quarterly finished goods declined from Sep. 2025 (€78.7 Mil) to Dec. 2025 (€69.5 Mil) and declined from Dec. 2025 (€69.5 Mil) to Mar. 2026 (€61.1 Mil).

Pacira BioSciences's annual finished goods increased from Dec. 2023 (€17.5 Mil) to Dec. 2024 (€45.0 Mil) and increased from Dec. 2024 (€45.0 Mil) to Dec. 2025 (€69.5 Mil).

Pacira BioSciences Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Inventories, Finished Goods Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.92 25.87 17.46 44.98 69.45

Pacira BioSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 51.42 83.36 78.74 69.45 61.14
FRA:82P
79GF Score
Pacira BioSciences Inc FRA:82P
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of €61.1 Mil mean?
Pacira BioSciences (FRA:82P) has a Inventories, Finished Goods of €61.1 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Inventories, Finished Goods too high?
Pacira BioSciences' current Inventories, Finished Goods is €61.1 Mil. Overall, Pacira BioSciences has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Inventories, Finished Goods compare to ETON and AMPH?
Pacira BioSciences' Inventories, Finished Goods of €61.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Drug Manufacturers company?
A good Inventories, Finished Goods depends on the Drug Manufacturers industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Inventories, Finished Goods is €61.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Inventories, Finished Goods of €61.1 Mil. The stock's GF Value™ is €25.64, compared to a current price of €22.00 — trading 14.2% below its estimated fair value. The current Inventories, Finished Goods is €61.1 Mil. Pacira BioSciences' overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Inventories, Finished Goods is €61.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.00 is trading 14.2% below its estimated GF Value™ of €25.64.

Key valuation signals for FRA:82P:

  • Inventories, Finished Goods: €61.1 Mil
  • GF Value™: €25.64 vs. price of €22.00 (14.2% below fair value)
  • GF Score™: 79/100 with 8 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
79GF Score

Get the complete analysis for FRA:82P

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.00
Price
€25.64
GF Value